Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04481932 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 22, 2020 (before its estimated June 2022 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
This study is a one-arm, open, phase II clinical study, and the study subjects are locally advanced and inflammatoryPatients with sexual or early HER2-positive breast cancer entered the trial period after signing informed consentTo evaluate trastuzumab combined with pyrrolitinib and chemotherapy regimen (TCbH+Py) for HER2 positive breastPathologic complete response rate (pCR) for adenocarcinoma.
Trial Details
NCT Number NCT04481932
Lead Sponsor Peking University
Conditions
(from sponsor)		 HER2-positive Breast Cancer
Enrollment 104 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov